paediatrics Brussels 17

AREN0532: Stage III FH Tumors

• 583 eligible patients met COG Stage III criteria; 40 pts excluded from analysis secondary to combined LOH 1p and 16 q • All received DD4A chemotherapy (vincristine, dactinomycin, doxorubicin) • Median follow-up: 42 months